Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2015-11-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
第三届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Guangdong Taicheng Pharmaceutical Co., Ltd. It details the election of the Supervisory Board Chairman, approval of changes in the use of raised funds, approval of a loan application for acquisition funds, and approval of an acquisition of a subsidiary. The document includes voting results and mentions that some matters will be submitted to the shareholders' meeting for approval. The content focuses on board/management decisions and resolutions rather than financial results, audit opinions, or regulatory filings. It is not a full annual or interim report, nor is it a call transcript or earnings release. The document is a formal announcement of board resolutions and management decisions, fitting the category of Board/Management Information (MANG). The document length is short (1837 characters), but it contains substantive content about board decisions, not just a notice or report publication announcement. Therefore, the appropriate classification is MANG with high confidence.
2015-11-30 Chinese
关于变更部分募集资金投资用途的可行性研究报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "Feasibility Study Report on the Change of Part of the Raised Funds Investment Usage" by Guangdong Taicheng Pharmaceutical Co., Ltd. It details the original investment projects funded by the company's IPO proceeds, the progress of these projects, reasons for changing the investment usage, and the new project to be implemented with the reallocated funds. The document includes detailed project descriptions, investment amounts, risk analysis, and concludes with a feasibility assessment. It is a comprehensive report focused on the company's capital investment and fundraising usage changes, not a general financial report, earnings release, or regulatory announcement. This type of document fits best under the category of Capital/Financing Update (CAP), as it concerns updates on the use of raised capital and investment projects. The document length (5912 characters) and detailed content confirm it is a full report rather than a brief announcement or certification. Therefore, the classification is CAP with high confidence.
2015-11-30 Chinese
关于召开2015年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening a 2015 fourth extraordinary general meeting of shareholders for Guangdong Taicheng Pharmaceutical Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures (both onsite and online), registration methods, and proxy forms. The document does not contain any financial statements, audit results, earnings data, or management discussion of financial performance. It is primarily an announcement and procedural guide for the shareholders' meeting, including agenda proposals to be voted on. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA) or a Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation materials or the actual voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document is over 5,000 characters and contains detailed meeting and voting information, consistent with PSI filings.
2015-11-30 Chinese
2015年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2015 third extraordinary general meeting of shareholders of Guangdong Taicheng Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on various proposals including board and supervisory committee elections, amendments to company bylaws, and legal opinions confirming the meeting's compliance with relevant laws. The content focuses on the official voting results and decisions made at the shareholders' meeting rather than the meeting materials or presentations. The document length is 4779 characters, which is sufficient to contain substantive voting results. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2015-11-27 Chinese
2015年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the convening, attendance, and voting procedures of a company's 2015 third extraordinary general meeting (临时股东大会). It details the meeting's date, location, voting methods, attendees, and the results of various resolutions, including board and supervisory committee elections and amendments to company bylaws. The document does not contain financial statements or financial performance data, nor is it a transcript or presentation. It is a legal opinion on the shareholder meeting's procedures and results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains detailed voting results, confirming it is not merely an announcement of a report but the actual voting results and legal opinion. Therefore, the correct classification is DVA with high confidence.
2015-11-27 Chinese
关于召开2015年第三次临时股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2015 third extraordinary general meeting of shareholders for Guangdong Taicheng Pharmaceutical Co., Ltd. It includes information about the meeting time, location, agenda items (such as board elections and amendments to company bylaws), voting procedures (including cumulative voting details), registration methods, and contact information. It also contains attachments like proxy forms and attendance receipts. The content focuses on informing shareholders about the meeting logistics and agenda, not the results of the vote or the meeting itself. This type of document is a notice or announcement related to a shareholders' meeting, specifically a notice of meeting and voting instructions, which fits the category of AGM Information (AGM-R). It is not a declaration of voting results (DVA), nor a proxy solicitation (PSI), as it does not solicit votes but informs about the meeting and voting process. The document length and detail confirm it is not a brief announcement or a report publication announcement. Therefore, the best classification is AGM Information (AGM-R).
2015-11-22 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.